Navigation Links
PharmaNet Announces Tender Offer and Consent Solicitation
Date:5/27/2011

f Notes tendered, which is an amount equal to the Total Consideration, less the Consent Payment, plus any accrued and unpaid interest on the Notes from the most recent interest payment date for the Notes up to, but not including, the payment date for such Notes. Holders of Notes tendered after the Consent Payment Deadline will not receive the Consent Payment.

Following receipt of the consent of the holders of at least 66 2/3% in aggregate principal amount of the outstanding Notes, the Company will execute a supplemental indenture effecting the proposed amendments. Notes tendered and consents delivered may not be withdrawn after 5:00 p.m., New York City time, on June 9, 2011, unless such deadline is extended or earlier terminated.

The Offer is being made in connection with the sale by JLL PharmaNet Holdings, LLC, a Delaware limited liability company, of all of the issued and outstanding shares of capital stock of PDGI Holdco, Inc., a Delaware corporation, a holding company that owns all of the issued and outstanding shares of capital stock of the Company, to inVentiv Health (the "Transaction").  The Offer is subject to a number of conditions that are set forth in the Offer to Purchase, including, without limitation, (i) the consummation of the Transaction, (ii) the receipt of the required consents to amend and supplement the indenture governing the Notes and (iii) the execution and delivery of a supplemental indenture effecting such amendments by the applicable parties, all as more fully described in the Offer to Purchase.

The Company has engaged Jefferies & Company, Inc. and UBS Securities LLC as Dealer Managers and Solicitation Agents for the Offer. Persons with questions regarding the Offer should contact Jefferies at (888) 708-5831 (toll free) or (203) 708-5831 (collect) or UBS Investment Bank at or (888) 719-4210 (toll free) or (203) 719-4210 (collect). Requests for copies of the Offer to Purchase or other tender offer materials m
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting
2. PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
3. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
4. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
5. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
6. Christopher Brennan Joins PharmaNet Development Group as General Counsel
7. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
8. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
9. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
10. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
11. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... CLEVELAND, Jan. 28, 2011 Arteriocyte®, a leading ... Ohio and Hopkinton, Massachusetts that develops proprietary stem ... approval from the Food and Drug Administration (FDA) ... its Magellan MAR01™ technology in the treatment of ...
... Reportlinker.com announces that a new ... its catalogue: ... Probes and Biochips -- New Product ... for Instrument and Reagent Suppliers ...
... Calif. and HOPKINTON, Mass., Jan. 27, 2011 ... (Nasdaq: CALP ) today announced a ... for next generation sequencing sample preparation on Caliper,s ... researchers to leverage NuGEN,s Ovation® and Encore™ reagent ...
Cached Biology Technology:Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 2Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 3Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 3
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Soil is the most species-rich microbial ecosystem ... certain species, give them access to the root and so ... then benefit in a variety of ways. To achieve this, ... of these bacteria are friends and which foes. Researchers from ...
... reported details of how certain drugs can precisely target ... replication. Since all strains of the virus require the ... drugs that can effectively treat new strains of the ... When new strains of influenza emerge, it can ...
... Results from a study conducted at Georgia State University ... intestines and the immune system, kicked off by another type ... disease. The study suggests that the "fight" continues after ... to Andrew Gewirtz, professor of biology at the GSU Center ...
Cached Biology News:Bacterial community inside the plant root 2Bacterial community inside the plant root 3Target for potent first-strike influenza drugs identified 2Target for potent first-strike influenza drugs identified 3Target for potent first-strike influenza drugs identified 4